Preferences for Tapering Biologic Disease‐Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment

Documenti analoghi

• Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders
  di: Yoshihiko Hoshida, et al.
  Pubblicazione: (2024)
• Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer
  di: Juan I. Ruiz, et al.
  Pubblicazione: (2024)
• Associations Between Changes in Pain Sensitization and Disease Activity Following Disease‐Modifying Antirheumatic Drug Therapy in Established Rheumatoid Arthritis
  di: Burcu Aydemir, et al.
  Pubblicazione: (2025)
• Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study
  di: Takafumi Aritomi, et al.
  Pubblicazione: (2026)
• Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
  di: Romain Aymon, et al.
  Pubblicazione: (2025)